Hjem › Eggstokkreft › Indiana › Indianapolis
Kliniske studier for Eggstokkreft i Indianapolis, IN
17 studier for Eggstokkreft søker deltakere på steder i og rundt Indianapolis (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruttererFase 1
- IU Simon Cancer Center, Indianapolis
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekruttererFase 2
- Indiana University Melvin and Bren Simon Cancer Center /ID# 275492, Indianapolis
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekruttererFase 2
- Site 0284 - Community Cancer Center North, Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers, Indianapolis
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- Franciscan Health, Indianapolis
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Indiana University (IU) School of Medicine, Indianapolis
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- Community Health Network, Indianapolis
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RekruttererFase 3
- Franciscan Health Indianapolis ( Site 0081), Indianapolis
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
RekruttererFase 3
- Indiana University Simon Comprehensive Cancer Center, Indianapolis
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruttererFase 1
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Riley Hospital for Children, Indianapolis
A Study to Test How Well Different Doses of BI 3820768 Are Tolerated by People With Advanced Cancer (Solid Tumours)
RekruttererFase 1
- Indiana University, Indianapolis
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekrutterer
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- Sidney and Lois Eskenazi Hospital, Indianapolis
- Ascension Saint Vincent Indianapolis Hospital, Indianapolis
- og 1 flere
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Community Health Network, Indianapolis
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
RekruttererFase 2/3
- Community Health Network - MD Anderson, Indianapolis
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RekruttererFase 1
- Community Health Network, Inc, Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network Investigational Drug Services, Indianapolis
- og 1 flere
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RekruttererFase 3
- Indiana University, Indianapolis
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i Indianapolis
- Ikke-småcellet lungekreft32 studier
- Kreft (alle typer)24 studier
- Hjertesvikt23 studier
- Fedme20 studier
- Brystkreft20 studier
- Metastatisk kreft19 studier
- Kolorektal kreft18 studier
- Kardiovaskulær sykdom17 studier
- Lungekreft16 studier
- Type 1-diabetes14 studier
- Endometriekreft14 studier
- Alzheimers sykdom14 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.